Revance Therapeutics (RVNC) Tops Q4 EPS by 13c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.71), $0.13 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank